New immunotherapy combo shows promise for tough cancers

NCT ID NCT06535607

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 participants will receive the treatment intravenously.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Volrustomig (an experimental immunotherapy) given alone or with chemotherapy drugs (cisplatin, carboplatin, paclitaxel, 5-FU)
What this could lead to: If successful, this could provide a new treatment option for people with advanced cancers that are hard to treat.
What could go wrong: This is an early-phase trial with only 257 participants, so results may not apply to everyone. Side effects from the immunotherapy or chemo could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer esophageal squamous cell carcinoma head and neck squamous cell carcinoma malignant pleural mesothelioma Squamous Cell Carcinoma of Head and Neck Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY) SUB-STUDY 2 HEAD AND NECK SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG MONOTHERAPY) SUB-STUDY 3 HEAD AND NECK SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG IN COMBINATION WITH CHEMOTHERAPY) SUB-STUDY 4 ESOPHAGEAL SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG IN COMBINATION WITH CHEMOTHERAPY) SUB-STUDY 5 UNRESECTABLE PLEURAL MESOTHELIOMA (VOLRUSTOMIG MONOTHERAPY)

Contacts and locations

Locations

Research Site
WITHDRAWN

Los Angeles, California, 90025, United States
Research Site
RECRUITING

Baltimore, Maryland, 21201, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10065, United States
Research Site
NOT_YET_RECRUITING

Stony Brook, New York, 11794, United States
Research Site
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
Research Site
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Research Site
RECRUITING

Clayton, 3168, Australia
Research Site
RECRUITING

Nedlands, 6009, Australia
Research Site
RECRUITING

Ijuí, 98700-000, Brazil
Research Site
RECRUITING

Londrina, 86015-520, Brazil
Research Site
NOT_YET_RECRUITING

Natal, 59075-740, Brazil
Research Site
NOT_YET_RECRUITING

Porto Alegre, 91350-200, Brazil
Research Site
NOT_YET_RECRUITING

Santo André, 09060-650, Brazil
Research Site
RECRUITING

São Caetano do Sul, 09541-270, Brazil
Research Site
RECRUITING

Vitória, 29043-260, Brazil
Research Site
NOT_YET_RECRUITING

Vitória, 29043-260, Brazil
Research Site
NOT_YET_RECRUITING

Edmonton, Alberta, T6G 1Z2, Canada
Research Site
RECRUITING

Montreal, Quebec, H2X 0A9, Canada
Research Site
NOT_YET_RECRUITING

Anyang, 455000, China
Research Site
NOT_YET_RECRUITING

Beijing, 100142, China
Research Site
RECRUITING

Beijing, 100142, China
Research Site
ACTIVE_NOT_RECRUITING

Beijing, 100730, China
Research Site
RECRUITING

Beijing, 100730, China
Research Site
ACTIVE_NOT_RECRUITING

Beijing, CN-100730, China
Research Site
WITHDRAWN

Bengbu, 233004, China
Research Site
WITHDRAWN

Changchun, 130021, China
Research Site
RECRUITING

Changchun, 130021, China
Research Site
RECRUITING

Changsha, 410003, China
Research Site
COMPLETED

Changsha, 410008, China
Research Site
RECRUITING

Changsha, 410008, China
Research Site
COMPLETED

Changsha, 410013, China
Research Site
COMPLETED

Chengdu, 610041, China
Research Site
ACTIVE_NOT_RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Chengdu, 610072, China
Research Site
ACTIVE_NOT_RECRUITING

Chongqing, 400030, China
Research Site
WITHDRAWN

Chongqing, 400030, China
Research Site
ACTIVE_NOT_RECRUITING

Dongguan, 523009, China
Research Site
RECRUITING

Dongguan, 523009, China
Research Site
COMPLETED

Fuzhou, 350011, China
Research Site
RECRUITING

Fuzhou, 350014, China
Research Site
NOT_YET_RECRUITING

Fuzhou, 350014, China
Research Site
NOT_YET_RECRUITING

Guangzhou, 510000, China
Research Site
ACTIVE_NOT_RECRUITING

Hangzhou, 310022, China
Research Site
RECRUITING

Hangzhou, 310022, China
Research Site
NOT_YET_RECRUITING

Harbin, 150081, China
Research Site
WITHDRAWN

Hefei, 230031, China
Research Site
RECRUITING

Jining, 272029, China
Research Site
COMPLETED

Kunming, 650118, China
Research Site
RECRUITING

Kunming, 650118, China
Research Site
TERMINATED

Nanchang, 330006, China
Research Site
NOT_YET_RECRUITING

Nanjing, 210009, China
Research Site
ACTIVE_NOT_RECRUITING

Nanning, 530021, China
Research Site
RECRUITING

Nanning, 530021, China
Research Site
RECRUITING

Shandong, 250117, China
Research Site
RECRUITING

Shandong, China
Research Site
COMPLETED

Shandong, China
Research Site
NOT_YET_RECRUITING

Shandong, China
Research Site
ACTIVE_NOT_RECRUITING

Shanghai, 200120, China
Research Site
RECRUITING

Shanghai, 200120, China
Research Site
ACTIVE_NOT_RECRUITING

Shenyang, 110004, China
Research Site
COMPLETED

Tianjin, 300060, China
Research Site
RECRUITING

Tianjin, 300060, China
Research Site
ACTIVE_NOT_RECRUITING

Wuhan, 430022, China
Research Site
RECRUITING

Wuhan, 430030, China
Research Site
RECRUITING

Wuhan, 430040, China
Research Site
WITHDRAWN

Wuhan, 430079, China
Research Site
RECRUITING

Wuhou District, 610041, China
Research Site
NOT_YET_RECRUITING

Zhengzhou, 450008, China
Research Site
NOT_YET_RECRUITING

Cologne, 51109, Germany
Research Site
NOT_YET_RECRUITING

Frankfurt, 60488, Germany
Research Site
RECRUITING

Gauting, 82131, Germany
Research Site
NOT_YET_RECRUITING

Großhansdorf, 22927, Germany
Research Site
RECRUITING

Hamburg, 21075, Germany
Research Site
RECRUITING

Heidelberg, 69120, Germany
Research Site
NOT_YET_RECRUITING

Mainz, 55131, Germany
Research Site
RECRUITING

Münster, 48153, Germany
Research Site
NOT_YET_RECRUITING

Offenbach, 63069, Germany
Research Site
RECRUITING

Regensburg, 93049, Germany
Research Site
NOT_YET_RECRUITING

Alessandria, 15100, Italy
Research Site
RECRUITING

Bergamo, 24125, Italy
Research Site
NOT_YET_RECRUITING

Orbassano, 10043, Italy
Research Site
NOT_YET_RECRUITING

Kashiwa, 277-8577, Japan
Research Site
NOT_YET_RECRUITING

Yokohama, 241-8515, Japan
Research Site
NOT_YET_RECRUITING

Incheon, 21565, South Korea
Research Site
RECRUITING

Namdong-gu, 21565, South Korea
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
NOT_YET_RECRUITING

Seoul, 03722, South Korea
Research Site
NOT_YET_RECRUITING

Kaohsiung City, 80756, Taiwan
Research Site
NOT_YET_RECRUITING

Kaohsiung City, 83301, Taiwan
Research Site
RECRUITING

Taichung, 40705, Taiwan
Research Site
RECRUITING

Taipei, 112, Taiwan
Research Site
NOT_YET_RECRUITING

Taipei, 112, Taiwan
Research Site
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Research Site
NOT_YET_RECRUITING

Glasgow, G12 0YN, United Kingdom
Research Site
RECRUITING

Manchester, M23 9LT, United Kingdom
Research Site
RECRUITING

Hanoi, 100000, Vietnam
Research Site
RECRUITING

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.